Research map: NF2 lacking exon 11 induced by antisense gene therapy is able to partially recover merlin deficiency in NF2-SWN iPSC-derived spheroid model

Back to the article

Papers in this map

  1. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 · Michael I. Love · 2014 · 104531 citations · Cited by this paper
  2. Decoding preeclampsia: A fusion of multi-view machine learning and multi-omics to identify putative inflammation-related mechanisms · 2026 · Related
  3. STAR: ultrafast universal RNA-seq aligner · Alexander Yu. Dobin · 2012 · 58150 citations · Cited by this paper
  4. Y-RNAs and their fragments reflect kidney injury in diabetic kidney disease · 2026 · Related
  5. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles · Aravind N. Subramanian · 2005 · 58106 citations · Cited by this paper
  6. Quieting the carrier: Matching delivery to immunology in anti-inflammatory mRNA therapy · 2026 · Related
  7. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data · Aaron McKenna · 2010 · 30730 citations · Cited by this paper
  8. Polyamines are i-Motif disruptors · 2026 · Related
  9. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features · Yang Liao · 2013 · 30442 citations · Cited by this paper
  10. Codon-Optimized Npc1 mRNA corrects Niemann-Pick type C1 disease phenotypes in vitro and in vivo · 2026 · Related
  11. GSVA: gene set variation analysis for microarray and RNA-Seq data · Sonja Hänzelmann · 2013 · 17099 citations · Cited by this paper
  12. Neonatal expression of human FMRP isoform corrects cortical deficits and improves behavior in a mouse model of fragile X syndrome · 2026 · Related
  13. Targeting Huntingtin Expression in Patients with Huntington’s Disease · Sarah J. Tabrizi · 2019 · 723 citations · Cited by this paper
  14. Intranasal Tat-modified PEG-PCL nanomicelles delivering anti-RelA siRNA attenuate ischemia-reperfusion injury in transient MCAO mice · 2026 · Related
  15. A joint NCBI and EMBL-EBI transcript set for clinical genomics and research · Joannella Morales · 2022 · 629 citations · Cited by this paper
  16. Antisense Peptide Nucleic Acids Targeting Ribosomal Protein Genes: A Novel Strategy Against Carbapenem-resistant Acinetobacter baumannii · 2026 · Related
  17. FDA-Approved Oligonucleotide Therapies in 2017 · Cy Aaron Stein · 2017 · 619 citations · Cited by this paper
  18. To scramble or not: steric blocking 2′-MOE/PS control antisense oligonucleotides across cellular models · 2026 · Related
  19. Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS · Jonathan S. Mill · 2020 · 567 citations · Cited by this paper
  20. ADAR RNA editing for cardiovascular disease: Targeting B4GALT1 to modulate lipid metabolism through reduced galactosyltransferase activity · 2026 · Related
  21. Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer · Yumeng Wang · 2018 · 534 citations · Cited by this paper
  22. Rank–rank hypergeometric overlap: identification of statistically significant overlap between gene-expression signatures · Seema B. Plaisier · 2010 · 528 citations · Cited by this paper
  23. Eteplirsen in the treatment of Duchenne muscular dystrophy · Kenji Rowel Q. Lim · 2017 · 506 citations · Cited by this paper
  24. Mutational and fitness landscapes of an RNA virus revealed through population sequencing · Ashley Acevedo · 2013 · 436 citations · Cited by this paper
  25. Antisense therapy for cancer · Martin Edwin Gleave · 2005 · 403 citations · Cited by this paper
  26. Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon · Yimin Hua · 2007 · 348 citations · Cited by this paper
  27. NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth · Marianne F. James · 2009 · 312 citations · Cited by this paper
  28. Treating Disease at the RNA Level with Oligonucleotides · Arthur Aaron Levin · 2019 · 299 citations · Cited by this paper
  29. Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation · Scott Randall Plotkin · 2022 · 298 citations · Cited by this paper
  30. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis · Rosanne M. Crooke · 2005 · 225 citations · Cited by this paper
  31. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs · Peter Sazani · 2001 · 217 citations · Cited by this paper
  32. Directed differentiation of human pluripotent cells to neural crest stem cells · Laura Menéndez · 2013 · 207 citations · Cited by this paper
  33. Merlin and the ERM proteins – regulators of receptor distribution and signaling at the cell cortex · Andrea I. McClatchey · 2009 · 206 citations · Cited by this paper
  34. The genomic landscape of schwannoma · Sameer Agnihotri · 2016 · 190 citations · Cited by this paper
  35. Genetic Severity Score predicts clinical phenotype in NF2 · Dorothy J. Halliday · 2017 · 151 citations · Cited by this paper
  36. Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma · Scott Randall Plotkin · 2019 · 129 citations · Cited by this paper
  37. The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration · Paymaan Jafar‐Nejad · 2020 · 129 citations · Cited by this paper
  38. Establishment of a benign meningioma cell line by hTERT-mediated immortalization · Sylvia Püttmann · 2005 · 117 citations · Cited by this paper
  39. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients · Adam T. Hexter · 2015 · 109 citations · Cited by this paper

Source: OpenAlex (CC0)